These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 30336730)

  • 1. Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate.
    Blom J; Löwbeer C; Elfström KM; Sventelius M; Öhman D; Saraste D; Törnberg S
    J Med Screen; 2019 Jun; 26(2):92-97. PubMed ID: 30336730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England.
    Moss S; Mathews C; Day TJ; Smith S; Seaman HE; Snowball J; Halloran SP
    Gut; 2017 Sep; 66(9):1631-1644. PubMed ID: 27267903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seasonal variations do not affect the superiority of fecal immunochemical tests over guaiac tests for colorectal cancer screening.
    Chausserie S; Levillain R; Puvinel J; Ferrand O; Ruiz A; Raginel T; Lantieri O; Launoy G; Guittet L
    Int J Cancer; 2015 Apr; 136(8):1827-34. PubMed ID: 25195670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-based colorectal cancer screening programmes using a faecal immunochemical test: should faecal haemoglobin cut-offs differ by age and sex?
    Arana-Arri E; Idigoras I; Uranga B; Pérez R; Irurzun A; Gutiérrez-Ibarluzea I; Fraser CG; Portillo I;
    BMC Cancer; 2017 Aug; 17(1):577. PubMed ID: 28851318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.
    Grobbee EJ; Wisse PHA; Schreuders EH; van Roon A; van Dam L; Zauber AG; Lansdorp-Vogelaar I; Bramer W; Berhane S; Deeks JJ; Steyerberg EW; van Leerdam ME; Spaander MC; Kuipers EJ
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD009276. PubMed ID: 35665911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
    Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
    Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy.
    Brenner H; Tao S
    Eur J Cancer; 2013 Sep; 49(14):3049-54. PubMed ID: 23706981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels.
    Hol L; Wilschut JA; van Ballegooijen M; van Vuuren AJ; van der Valk H; Reijerink JC; van der Togt AC; Kuipers EJ; Habbema JD; van Leerdam ME
    Br J Cancer; 2009 Apr; 100(7):1103-10. PubMed ID: 19337257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
    Tinmouth J; Lansdorp-Vogelaar I; Allison JE
    Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening.
    Raginel T; Puvinel J; Ferrand O; Bouvier V; Levillain R; Ruiz A; Lantieri O; Launoy G; Guittet L
    Gastroenterology; 2013 May; 144(5):918-25. PubMed ID: 23376426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited.
    Digby J; Fraser CG; Carey FA; Lang J; Stanners G; Steele RJ
    J Med Screen; 2016 Sep; 23(3):130-4. PubMed ID: 26589788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting compliance in faecal occult blood testing: a cluster randomized study of the faecal immunochemical test versus the guaiac faecal occult test.
    Birkenfeld S; Belfer RG; Chared M; Vilkin A; Barchana M; Lifshitz I; Fruchter D; Aronski D; Balicer R; Niv Y; Levi Z
    J Med Screen; 2011; 18(3):135-41. PubMed ID: 22045822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interval cancers in a national colorectal screening programme based on faecal immunochemical testing: Implications for faecal haemoglobin concentration threshold and sex inequality.
    Clark GR; Godfrey T; Purdie C; Strachan J; Carey FA; Fraser CG; Steele RJ
    J Med Screen; 2024 Mar; 31(1):21-27. PubMed ID: 37469171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of advanced colorectal neoplasia and relative colonoscopy workloads using quantitative faecal immunochemical tests: an observational study exploring the effects of simultaneous adjustment of both sample number and test positivity threshold.
    Young GP; Woodman RJ; Symonds E
    BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32994195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic yield of a one sample immunochemical test at different cut-off values in an organised screening programme for colorectal cancer.
    Hamza S; Dancourt V; Lejeune C; Bidan JM; Lepage C; Faivre J
    Eur J Cancer; 2013 Aug; 49(12):2727-33. PubMed ID: 23601670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits of switching from guaiac-based faecal occult blood to faecal immunochemical testing: experience from the Wallonia-Brussels colorectal cancer screening programme.
    Guo F; De Brabander I; Francart J; Candeur M; Polus M; Van Eycken L; Brenner H
    Br J Cancer; 2020 Mar; 122(7):1109-1117. PubMed ID: 32066910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with a two-tier reflex gFOBT/FIT strategy in a national bowel screening programme.
    Fraser CG; Digby J; McDonald PJ; Strachan JA; Carey FA; Steele RJ
    J Med Screen; 2012 Mar; 19(1):8-13. PubMed ID: 22156144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colonoscopy findings after increasing two-stool faecal immunochemical test (FIT) cut-off: Cross-sectional analysis of the SCREESCO randomized trial.
    Westerberg M; Eriksson J; Metcalfe C; Löwbeer C; Ekbom A; Steele R; Holmberg L; Forsberg A
    J Intern Med; 2024 Aug; 296(2):187-199. PubMed ID: 38845164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised comparison of two faecal immunochemical tests in population-based colorectal cancer screening.
    Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mundt MW; Spijker WJ; Bongers EJC; Kuipers EJ; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
    Gut; 2017 Nov; 66(11):1975-1982. PubMed ID: 27507905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.